← All trials
NCT06106971
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2018
- Primary completion
- Jun 30, 2025
- Completion date
- Jun 30, 2025
- First posted
- Oct 30, 2023
- Last posted
- Oct 30, 2023
- Enrollment
- 68
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kaohsiung Medical UniversityLead sponsor
- Kaohsiung Medical UniversityOverall official - principal investigator
- Kaohsiung Medical UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.